Monsanto and GlaxoSmithKline are joining founder investor Atlas Venture in financing RaNA Therapeutics, which specialises in genetic research.
Biopharmaceutical company RaNA Therapeutics closed a $20.7m series A round on Wednesday co-led by GlaxoSmithKline’s corporate venturing unit, SR One, as well as agricultural corporation Monsanto and venture capital firm Atlas Venture.
Atlas was previously a co-founder of RaNA, and provided $2.7m in seed capital last year when RaNA was in stealth mode.
The three were joined in the round by the Partners Innovation Fund, a venturing fund jointly representing Brigham and Women’s Hospital and Massachusetts General Hospital.
…
